Safe Save Medical Cell Sciences & Technology

Executive Summary

Safe Save Medical Cell Sciences & Technology is a Taiwanese biotechnology company focused on developing autologous dendritic cell-based cancer immunotherapies. Its proprietary ADCTA (Autologous Dendritic Cells/Tumor Antigens) platform creates patient-specific vaccines that stimulate anti-tumor immune responses, targeting solid tumors with high unmet need, particularly glioblastoma. Founded in 2011 and based in Zhubei, the company is privately held and currently in the preclinical stage, with a team of 50–200 employees. The ADCTA platform leverages the patient's own dendritic cells loaded with tumor antigens, aiming to induce a robust and durable immune response against malignant cells. This personalized approach positions Safe Save at the forefront of precision oncology, addressing the limitations of standard treatments for aggressive cancers like glioblastoma. Despite its promising platform, Safe Save is at an early development stage with no clinical data yet disclosed. The company faces typical preclinical risks, including manufacturing scalability and regulatory hurdles. However, its focus on high-need indications and a differentiated autologous vaccine strategy could attract partnerships or funding to advance toward the clinic. Upcoming milestones include preclinical data publications and potential IND submissions, which will be critical for value inflection. The company's ability to demonstrate efficacy and safety in animal models and navigate regulatory pathways will determine its trajectory. Overall, Safe Save represents an early-stage investment opportunity with significant upside contingent on successful development.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical data for lead glioblastoma candidate in a peer-reviewed journal80% success
• Q4 2026Submission of IND application for ADCTA glioblastoma therapy60% success
• Q1 2027Completion of Series B financing round to support clinical development50% success